Theme: Revolutionary Essence of Motivating the Living and Good Health of Women
Gynec & Preventive Oncology 2017
3rd Annual Conference on Gynecologic Oncology & Preventive Oncology
Dates : July 20-21, 2017
Venue : Chicago, Illinois, USA
Theme : Revolutionary Essence of Motivating the Living and good health of Women
ConferenceSeries Ltd invites all the participants across the globe to attend the "3rd Annual Conference on Gynecologic Oncology & Preventive Oncology” slated on July 20-21, 2017 Chicago, Illinois, USA.
Global Gynecology Cancer conferences provides two day of robust discussions on methods and strategies related to management and quality improvement of Cancer therapy as well as explore new ideas and concepts on a global scale and topics include ovarian cancer, Breast cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer.
In support of improving patient care, this activity has been planned and implemented by Conference Series, Ltd and Center for Education Development (CED). CED is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Center for Education Development designates the live format for this educational activity for AMA PRA Category 1 Credits™ and ANCC credit. Participants should only claim credit commensurate with the extent of their participation in the activity. Full accreditation information including disclosures, credit hours available and faculty information will be provided in the attendee handout onsite.
Nearly 80,000 women are diagnosed with Oncology Gynecology in the United States, and half of those are uterine cancer diagnoses with a mortality of 8,000 women per year. Ovarian cancer found to be the 2nd most common Oncology Gynecology with about 22,000 new cases per year, leading to 16,000 deaths yearly. Mortality for cervical cancer have decreased as Pap smears have become commonplace. Still, there are about 12,000 diagnoses every year with about 4,200 women die from this disease annually. Vulvar and vaginal cancer are relatively rare and when caught and treated early offers of reasonably good prognosis. 4,500 women are diagnosed with vulvar cancer each year, with about 950 women die from it. Vaginal cancer, meanwhile, account for about 2,600 diagnoses per year, and about 840 deaths. Every woman is at risk for developing a Oncology Gynecology. It is estimated that there will be about 98,000 new cases diagnosed and approximately 30,000 deaths from Oncology Gynecology in the United States during 2015 as per American Cancer Society. Out of which Uterine cancer has the large portion about 50% of cases with an estimated mortality rate of 18.5%. The Ovarian cancer has the highest estimated mortality rate at 66%.
ConferenceSeries Ltd which is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical(Cancer meeting,cancer conferences, oncology society, European oncology conferences, surgical oncology,global cancer conference, cancer conferences, American oncology society), Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.
Why to attend ?
With members from around the world focused on learning about Oncology Gynecology; this is your best opportunity to reach the largest assemblage of participants from the Gynecologists community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Gynecologic Cancers are hallmarks of this conference.
Speakers will include world renowned experts in all disciplines, offering a unique opportunity to highlight new technologies in all aspects of breast healthcare.
The congress program includes speakers who are the world’s leading Gynecology & breast healthcare specialists.
· Networking opportunities.
· Welcome Reception to mingle with speakers and society leadership.
· Meet the Expert Sessions.
· Relationship building opportunities throughout the congress.
· Educational sessions and special events.
· Professional Trade Exhibition.
· Morning and afternoon refreshment breaks
· Allied Health Professionals
· Oncology Gynecology Associations and Societies
· Business Entrepreneurs
· Software Developing Companies
· Medical Devices Companies
· Biomedical Companies
· Biotechnology Companies
· Data Management Companies
ConferenceSeries Ltd cancer conferences invites all the participants from all over the world to attend ‘3rd Annual Conference on Gynecologic Oncology & Preventive Oncology’ during July 20-21, 2017 Chicago, Illinois, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Global Gynecology Oncology 2017 is a platform to discuss and learn about Cause of the cancer it’s Symptoms, Pathogenesis, Types, Tests, Screening, Diagnosis and Monitoring Gynecology Treatment, Surgical Methods, Prevention, clinical trials and research, Sexual and reproductive issues and Role of imaging in Gynecology Oncology conferences Gynecology Oncology, Ovarian Cancer, Breast Cancer, Uterine Cancer, Vaginal cancer, Cervical Cancer, and Vulvar Cancer , Gynecology & obstetrics, Heredities in Obs and Gyn, Treatments in Pregnancy, Breast Disease, Prenatal Diagnosis, Gynecology & surgical procedure, Gynecologic cancers, Critical care in women health, Contraception, Health related Behaviours In Women, Infertility, Nursing and Health care, Gynecological Endocrinology, Uro gynecology, Maternal-fetal medicine, Sexually transmitted Disease, Vulvar and Vaginal Disease, Reproductive medicine & Immunology, Pelvic and Sexually Transmitted Infection, Nutrition in Cancer Care
Track 1: Gynecologic Oncology
Gynecology Oncology is the study about any cancer that begins in a woman's reproductive organs. The five Gynecologic cancers starts in the woman's pelvis at different places. Each cancer is unique by its symptoms, signs, risk factors and in their strategies of prevention. All these five different types of Gynecology Cancers risk increases with the age. When these cancers were diagnosed at their early stages, the treatment will be more efficient.The five major types of cancer affect a woman's reproductive organs are ovarian, uterine, cervical,vulvar, and vaginal cancer. All these as a group are known as Gynecologic cancers
Track 2: Breast Cancer
Breast cancer is the most common invasive Oncology Gynecology in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers in women. 18.2% of all cancer deaths worldwide, including both males and females, are from breast cancer. Breast cancer rates are much higher in developed nations compared to developing ones. There are several reasons for this, with possibly life-expectancy being one of the key factors - breast cancer is more common in elderly women; women in the richest countries live much longer than those in the poorest nations. The different lifestyles and eating habits of females in rich and poor countries are also contributory factors, experts believe.
Track 3: Ovarian Cancer
Ovarian cancer is most common in Gynecologic Cancers in women who have been through the menopause (usually over the age of 50), although it can affect women of any age. As the symptoms of ovarian cancer can be similar to those of other conditions, it can be difficult to recognise. However, there are early symptoms to look out for, such as persistent bloating, pain in the pelvis and lower stomach, and difficulty eating. The treatment you receive for ovarian cancer will depend on several things, including the stage of your cancer and your general health. Chemotherapy is the main treatment for ovarian cancer, but your treatment will usually involve a combination of surgery and chemotherapy.
Track 4: Endometrial Cancer
Endometrial cancer is a type of cancer that begins in the uterus. The uterus is the hollow, pear-shaped pelvic organ in women where fetal development occurs. Endometrial cancer is often detected at an early stage because it frequently produces abnormal vaginal bleeding, which prompts women to see their doctors. If endometrial cancer is discovered early, removing the uterus surgically often cures endometrial cancer. Endometrial cancer can spread to other parts of your body, making it more difficult to treat successfully. Endometrial cancer that spreads (metastasizes) most often travels to the lungs.
Track 5: Cervical Cancer
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause. Almost all cases of cervical cancer are caused by the human papilloma virus (HPV). HPV is a very common virus that can be passed on through any type of sexual contact with a man or a woman. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor.
Track 6: Uterine Cancer
Uterine cancer is the most common cancer of a woman’s reproductive system. Uterine cancer begins when normal cells in the uterus change and grow uncontrollably, forming a mass called a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can spread to other parts of the body. There are two major types of uterine cancer 1)Adenocarcinoma. This makes up more than 80% of uterine cancers. It develops from cells in the lining of the uterus called the endometrium. 2)Sarcoma type of uterine cancer develops in the supporting tissues of the uterine glands or in the myometrium, which is the uterine muscle.
Track 7: Vulvar/Vaginal cancer
Vulvar cancer is a rare type of Oncology Gynecology cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Radiation therapy may be used in more advanced vulvar cancer cases when disease has spread to the lymph nodes and/or pelvis. It may be performed before or after surgery. Women with vulvar cancer should have routine follow-up and exams with their oncologist, often every 3 months for the first 2–3 years after treatment. They should not have routine surveillance imaging to monitor the cancer unless new symptoms appear or tumor markers begin rising. Imaging without these indications is discouraged because it is unlikely to detect a recurrence or improve survival and is associated with its own side effects and financial costs.
Track 8: Gynecology & Obstetrics
Gynecology & Obstetrics is the medical and surgical specialty that focuses on the research prospectus of reproductive system in females that includes Archives of Gynecology & Obstetrics,especially the diagnosis and treatment of disorders affecting the female reproductive organs.It deals with the study of diseases of the female reproductive organs, including the breasts
Track 9: Cancer Drugs
The implementation of new drug treatments has improved the prognosis for advanced cancers of the cervix, uterus, and ovary. Platinum analogs are the most effective drugs in the treatment of ovarian cancer. Fertility drugs (FD) are spreading worldwide fast and therefore many studies have reviewed the possible association between the use of these drugs and cancer. Since the drugs used for ovulation induction during in vitro fertilization (IVF) like hCG, hMG, rFSH increase the levels of gonadal hormones, concerns have grown regarding the risk of developing cancer in breast, ovary, endometrium, and other target organs.If the treatment plan involves chemotherapy you may experience physical, emotional, and/or psychological side effects related to this treatment. The side effects of ovarian cancer treatment depend on the type of treatment and may be different for each woman.
Track 10: Gynecologic Oncology: Pathogenesis
Gestational trophoblastic disease (GTD) is the general name for a group of rare tumors that occur during pregnancy in the fetalchorion, GTD can occur in any kind of pregnancy which is almost always curable if found early in Oncology Gynecology Pathogenesis. Uterine leiomyosarcoma (LMS) is a rare uterine malignancy it is an aggressive tumor associated with a high risk of recurrence and death, regardless of stage.Choriocarcinoma is a cancer that develops most commonly from abnormal placenta and it is nearly 100% curable if appropriate chemotherapy is administered after the tumor mass is separated from inside the uterus.
Track 11: Gynecologic Surgery
In Oncology Gynecology the Gynecologic Surgical methods include- Initial Debulking surgery, which may be performed by variety of procedures depending on the type & stage of ovarian cancer based on individual fertility concerns. The procedure for removal of ovary and fallopian tubes is known as Bilateral salpingo-oophorectomy surgery. The surgical removal of uterus and cervix is known as.Total hysterectomy. Lymph node biopsy will be performed by collecting the fluid sample from the abdomen. Omentectomy is surgical process for removing of omentum partially or as a whole. Fold of fatty tissue inside the abdomen is known as Omentum.
Track 12: Role of imaging in Gynecologic Oncology
Oncology Gynecology the endometrial cancer, MRI is used to identify myometrial invasion and extrauterine disease, allowing preoperative surgical planning in women with serious comorbidity. In cervical cancer, MRI has an established role in local staging. By assessing the proximal extension of tumours in young women, MRI determines the feasibility of fertility-preserving surgery. It is also used to plan and administer radiotherapy. This optimises tumour radiation, while limiting unwanted radiation to the bowel and other pelvic organs.Gynecologic Cancer the ovarian cancer, MRI is useful in young women as it is superior to ultrasound in diagnosing endometriomas, dermoids and fibroids, which can be misdiagnosed by ultrasound as malignant lesions.
Track 13: Clinical Gynecologic Oncology
Clinical Gynecologic Oncology is a specialized clinical field of medication that emphasis on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. As consultants, they have all-encompassing preparation in the identification and treatment of these cancers.
Track 14: Nursing and Health care
As the world becomes more complex and knowledge in every field becomes more extensive and detailed, it’s increasingly difficult to master everything in any one area. This is certainly true in the field of Gynecologists practice, which is undoubtedly one of the reasons for the recent trend towards specialization. However, this is only one of many factors contributing to the shift. Today, the multitude of pressures affecting Radiologists in general—and comprehensive Gynecologists in particular has become so oppressive that many doctors wonder whether comprehensive Gynecologists can survive.
Gynecologic Cancer Statistics
Gynecologic cancers are categorized by uncontrolled growth and spread of abnormal cells. These cancers originate in the female reproductive organs such as uterus, cervix, ovaries, vagina , vulva and Breast cancer. Several factors are responsible for the occurrence of these cancers. It includes various classes of cancer originating genes, known as oncogenes, which promotes the abnormal growth of cells. The abnormal function of these genes regulates through aging, smoking and environmental influences. In adding, infertility, obesity, mutations, early start of menstruation and late start of menopause also causes gynecologic cancers.
Gynecologic cancers are also originated by some viruses. For instance, almost all cervical cancers and vaginal and vulva cancers are caused by human papillomavirus (HPV). These gynecologic cancers are treated by medication therapies, radiation therapy, surgeries and chemotherapy. Treatments of these cancers are depends upon the type and different stages of cancers.
The global gynecologic cancers market is categorized based on various types of cancers and their treatment therapies. It includes uterine, ovarian cancer, vaginal cancer, vulvar cancer and cervical cancer.
Uterine cancer is also known as endometrial cancer. It is the most common type of gynecologic cancer. Major risk factors of uterine cancer include the use of estrogen without progesterone, hypertension, diabetes, tamoxifen, obesity and later age of menopause. Obese women have higher circulating levels of estrogen, which increases their risk for uterine cancer. Cervical cancer is the second most common type of gynecologic cancer. Ovarian cancer is mainly divided into three types: germ cell cancer, epithelial ovarian cancer and stromal ovarian cancer. Vulvar and vaginal cancers are rarest forms of gynecologic cancer. It usually affects women with age group of 50-70 years.
In terms of geographic, North America and Europe dominates the global gynecologic cancers market. The U.S. represents the largest market for gynecologic cancers followed by Canada in North America. In Europe, France, Germany and the U.K. holds major share of gynecologic cancers market. However, Asia is expected to show high growth rates in the next five years in global gynecologic cancers market. This is due to increasing awareness among people about various types of gynecologic cancers in the region. Japan, China and India are expected to be the fastest growing gynecologic cancers markets in Asia.
However, patent expiry of various major drugs is key restraint for the global gynecologic cancers market. In addition, stringent regulatory hurdles also obstruct the growth of global gynecologic cancers market. Advancement in personalized medicines holds immense potential for the growth of global gynecologic cancers market. Increasing mergers and acquisitions between drugs manufacturing companies and government bodies is key trend of global gynecologic cancers market.
Breast cancers can start from different parts of the breast. Most breast cancers begin in the ducts that carry milk. A small number of cancers start in other tissues in the breast. These cancers are called sarcomas and lymphomas and are not really thought of as breast cancers. If cancer cells have spread to your lymph nodes, there is a higher chance that the cells could have spread (metastasized) to other sites in your body. The more lymph nodes with breast cancer cells, the more likely it is that the cancer may be found in other organs as well. Because of this, finding cancer in one or more lymph nodes often affects your treatment plan. Usually, surgery to remove one or more lymph nodes will be needed to know whether the cancer has spread there.Still, not all women with cancer cells in their lymph nodes develop metastases, and some women can have no cancer cells in their lymph nodes and later develop metastases.
Scope and Importance of Gynecologic Oncology Research
Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer death in females’ worldwide, accounting for 9% (529,800) of the total new cancer cases and 8% (275,100) of the total cancer deaths among females. More than 85% of these cases and deaths occur in developing countries.
Tumor biology early detection, and treatment of ovarian cancer in older women as compared to younger women suffering with this malignancy. Effort was devoted to the type of problems met in conducting the analyses and, where data were inadequate, recommending research guidelines or approaches.
The center are at the forefront of research in the early discovery of ovarian cancer and uterine cancer , which is involved in developing blood tests to precisely determine the absence or presence of early stage ovarian cancer before it reveals, as well as on going translational research programs for all Gynecologic Cancers. Physicians are also involved in leading-edge programs in the prevention of cervical cancer through regular screenings and the identification of precancerous cervical lesions associated with papilloma virus infections.
Organized screening procedures can support to detect Gynecologic Cancer, including cervical cancer, uterine cancer, and ovarian cancer, early.
A pap smear can identify cervical and uterine cancers. It is suggested to begin analysis every three years early at age 21.
A pelvic exam images the rectum, vagina, cervix, fallopian tubes, uterus, ovaries, and Pelvic tests should be done annually, beginning at 21 and can help detect irregularities of the female reproductive system.
An endometrial tissue sample checks for abnormal cells or signs of uterine cancer which can be done for women with a high risk for endometrial cancer due to an inborn susceptibility or when there are symptoms that need to be evaluated.
Why it’s in Chicago, USA.
Gynecologic Cancer confers a large burden among women in the United States. Several evidence-based interventions are available to reduce the incidence, morbidity, and mortality from these cancers. The National Comprehensive Cancer Control Program (NCCCP) is uniquely positioned to implement these interventions in the US population. Every woman is at risk for developing a Gynecologic Cancer & Breast Cancer. It is estimated that there will be about 91,000 new cases diagnosed and approximately 28,000 deaths from Gynecologic Cancers in the United States during 2014.Post-menopausal women aged 45–70 years have the highest risk of developing uterine cancer. It is more common in Caucasian women than in other populations. Women living in North America or Europe develop uterine cancer more often than those living in other parts of the world. Women in higher income groups also tend to be affected more often than women in lower income groups.
Hospitals Associated with Gynecologic Oncology Research
Major Gynecologic Oncology associated hospitals in Chicago are around 2% when compared to worldwide.
Hospitals in Chicago and USA are:
- Methodist Hospital
- Southwest General Hospital
- Cancer Care Centers of South Texas
- Methodist Women's Center
- Metropolitan Methodist Hospital
- South Texas Oncology Group
- Advocate Good Samaritan Hospital
- Anderson Hospital
- Aspirus Wausau Hospital
- Aultman Hospital
- Aurora St. Luke's Medical Center
- Banner Good Samaritan Medical Center
- Barnes-Jewish Hospital
- Beaumont Hospital
- Bon Secours Memorial Regional Medical Center
- Boone Hospital Center
- Boston Medical Center
- Brigham and Women's Hospital
- Bryn Mawr (Pa.) Hospital
- Carle Foundation Hospital
- Cedars-Sinai Medical Center
- Christiana Hospital
- Dartmouth-Hitchcock Medical Center
- Duke University Hospital
- Emory University Hospital
- Evanston (Ill.) Hospital
- Fairview Southdale Hospital
- Flagler Hospital
- Florida Hospital
- Glendale (Calif.) Memorial Hospital and Health Center
- Gundersen Lutheran Medical Center
- Hackensack (N.J.) University Medical Center
- Halifax Health Medical Center of Daytona Beach
- Hutzel Women's Hospital
- Hartford (Conn.) Hospital
- Holy Cross Hospital
- Hospital of the University of Pennsylvania
- Huntington Hospital
- Indiana University Health Methodist Hospital/University Hospital (Indianapolis)
- Ingalls Memorial Hospital
- Inova Fairfax Hospital
- Johns Hopkins Hospital
- Keck Hospital of the University of Southern California
- Lancaster (Pa.) General Hospital
- LDS Hospital
- Magee-Womens Hospital of UPMC
- Massachusetts General Hospital
- MedStar Georgetown University Hospital
- Memorial Hermann Memorial City Medical Center
Societies Associated with Gynecologic Oncology Research
In world there are about 9,685 societies which are specifically associated with Gynecologic Oncology, in which 1289 societies are from USA and the remaining 269 societies are from Chicago.
American gynecologic and obstetrics society
American society of clinical oncology
National cancer institute
Society of Gynecologic Oncology
Society of Gynecologic nurse Oncologists
International Gynecologic cancer society
American college of Phlebology
American congress of Obstetricians and Gynecologists
Asian Society of Gynecologic Oncology
Female Genital Tract Pathology
Foundation for Women's Cancer
GYN-ONC - Gynecologic Cancers Support Group
Gynecologic Oncology Group
Northern Gynecologic Oncology Centre
Queensland Centre for Gynecologic Oncology
Industries Associated with Gynecologic Oncology Research
Industries associated with Gynecologic cancer over all world is about 85% in which 12% of industries are in USA and in Chicago about 3%.
· Johnson & Johnson
· Bristol-myers squibb
· Eli Lilly
· Merck & Co.
Universities Associated with Gynecologic Oncology Research
Gynecologic cancer associated universities in world are about 3284, in USA 612 universities.
St. Mary's University
Our Lady of the Lake University
Baptist University of the Americas
University of Texas Medical Branch
University of Texas Medical School at Houston
University of Texas Rio Grande Valley School of Medicine
Dell Medical School at The University of Texas at Austin
University of Alabama School of Medicine
University of Arizona College of Medicine
Charles R. Drew University of Medicine and Science
Keck School of Medicine of University of Southern California
Loma Linda University School of Medicine
Stanford University School of Medicine
UC Davis School of Medicine
University of California, Irvine School of Medicine
David Geffen School of Medicine at UCLA
UC Riverside School of Medicine
University of California, San Diego School of Medicine
University of Colorado School of Medicine
Frank H. Netter M.D. School of Medicine at Quinnipiac University
University of Connecticut School of Medicine
Yale School of Medicine
George Washington University Medical School
Georgetown University School of Medicine
Howard University College of Medicine
The University of Texas at San Antonio
The University of Texas Health Science centre at San Antonio
Florida Atlantic University Charles E. Schmidt College of Medicine
Florida State University College of Medicine
University of Florida College of Medicine
University of South Florida College of Medicine
Mercer University School of Medicine
Loyola University Chicago Stritch School of Medicine
Northwestern University Feinberg School of Medicine
Rush Medical College
Indiana University School of Medicine
University of Iowa Roy J. and Lucille A. Carver College of Medicine
University of Kansas School of Medicine
University of Kentucky College of Medicine
University of Louisville School of Medicine
Louisiana State University School of Medicine in New Orleans
Tulane University School of Medicine
Johns Hopkins University School of Medicine
Boston University School of Medicine
Harvard Medical School
Oakland University William Beaumont School of Medicine
Wayne State University School of Medicine
Mayo Clinic College of Medicine
University of Minnesota Medical School
University of Mississippi School of Medicine
University of Missouri-Columbia School of Medicine
Rutgers New Jersey Medical School
University of New Mexico School of Medicine
Icahn School of Medicine at Mount Sinai
New York Medical College
New York University School of Medicine
Market Value on Gynecologic Oncology Research
The global Gynecologic cancer market in 2010 was valued at $54bn, an increase of 5.1% over the previous year‘s sales of $51.3bn, and is forecasted to grow at a CAGR of 6.9% from 2010–16, reaching $81bn in 2016. Collectively, the seven major markets (US, 5EU, and Japan) represented 79.1% (or $43bn) of in the global cancer market in 2010. In terms of size, the US dominated the global cancer market, with 2010 sales of $21bn and a market share of 38.5%. The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. Collectively, the leading 10 brands accounted for almost 58.2% (or $31.4bn) of the global cancer market in 2010. In 2010 antineoplastics was the leading drug class in the global cancer market. The global antineoplastic market was valued at $46bn in 2010 at a year-on-year (Y-o-Y) growth of 7.3%. The major drugs that contributed to the 2010 sales in the antineoplastic category were Roche‘s Avastin (bevacizumab) at $6.2bn, Herceptin (trastuzumab) at $5.2bn, and MabThera (rituximab) at $5.1bn, with Y-o-Y sales growth of 3.8%, 3.1%, and 3.3% respectively. The cytostatic hormonal market registered 2010 sales of $8bn at a Y-o-Y decline of 6.5%. AstraZeneca‘s Arimidex (anastrozole) and Novartis‘s Femara (letrozole) led this class, reaching sales of $1.5bn and $1.3bn respectively in 2010.
- Gynecologic Oncology
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer
- Uterine Cancer
- Vulvar/ Vaginal cancer
- Cancer Drugs
- Gynecologic Oncology: Pathogenesis
- Gynecologic Surgery
- Role of Imaging in Gynecologic Oncology
- Clinical Gynecologic Oncology
- Nursing and Health care
- Nutrition in Cancer Care
- Gynecology & Obstetrics
To share your views and research, please click here to register for the Conference.
Thank you for your kind remarks and for including me. You were able to attract good speakers of excellent reputation.Sandra S Hatch, The University of Texas Medical Branch, USA
I was very glad to have been invited and to have had the chance to participate in this congress. Very high level of scientific discussion and presentations (which were of enough length for researches to be shared with the participants of the congress from all over the world).Kennedy Gonçalves Pacheco, Vascular Surgeon and Phlebologist, Brazil
Thanks for your holding the conference which provide a good opportunity of study! Accommodation is excellentXueqing Wang, Beijing Jishuitan Hospital, China
The meeting was well-organized. All the speakers did well, speaking to the point and keeping time, as well as the discussions were lively and well-informed. I had the opportunity to meet and share my work with many distinguished faculty from around the world, and collaborating with themKannan Vaidyanathan, Pushpagiri Institute of Medical Science & Research Center, India